Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 24;10(19):4352.
doi: 10.3390/jcm10194352.

The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial

Affiliations

The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial

Li-Wei Chen et al. J Clin Med. .

Abstract

This was a prospective, randomized, open-label trial. Patients without previous Helicobacter pylori eradication therapy were randomly assigned to either a high-dose dual therapy (HDDT) group or a traditional clarithromycin/amoxicillin triple therapy (CATT) group. In the HDDT group, patients took rabeprazole, 20 mg, four times per day for three days and then dual therapy with rabeprazole, 20 mg, and amoxicillin, 500 mg, four times per day during the patient's breakfast, lunch, dinner, and bedtime for 14 days. In the CATT group, patients received conventional triple therapy for 14 days (rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice per day). In the HDDT group, the success rates of H. pylori eradication were 91.7% (95% confidence interval (CI): 0.78-0.97) by intention-to-treat (ITT) and 94.3% (95% CI: 0.79-0.99) by per-protocol (PP) analysis. In the CATT group, the eradication rates were 77.1% (95% CI: 0.61-0.87) by ITT and 84.3% (95% CI: 0.66-0.94) by PP analysis. The study completion rates were 97.2% (35/36) in the HDDT group. Three-day high-dose rabeprazole induction treatment before dual therapy and a schedule of taking the drug at meal and bed times could achieve an acceptable H. pylori eradication rate (>90%) and good drug compliance.

Keywords: Helicobacter pylori; amoxicillin; combination; drug therapy; proton pump inhibitor; rabeprazole.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests that might be perceived to influence the results and/or the discussion reported in this article.

Figures

Figure 1
Figure 1
Study diagram.

References

    1. McColl K.E.L. Helicobacter pylori infection. N. Engl. J. Med. 2010;362:1597–1604. doi: 10.1056/NEJMcp1001110. - DOI - PubMed
    1. Malfertheiner P., Megraud F., O’Morain C.A., Atherton J., Axon A.T.R., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T. Management of Helicobacter pylori infection: The Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–664. doi: 10.1136/gutjnl-2012-302084. - DOI - PubMed
    1. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. doi: 10.1136/gut.2009.192757. - DOI - PubMed
    1. Vakil N., Vaira D. Treatment for H. pylori infection: New challenges with antimicrobial resistance. J. Clin. Gastroenterol. 2013;47:383–388. doi: 10.1097/MCG.0b013e318277577b. - DOI - PubMed
    1. Megraud F., Lehours P. Helicobacter pylori delection and antimicrobial susceptibility testing. Clin. Microbiol. Rev. 2007;20:280–322. doi: 10.1128/CMR.00033-06. - DOI - PMC - PubMed

LinkOut - more resources